The AHA today expressed support for the Closing Loopholes for Orphan Drugs Act, H.R. 4538, bipartisan legislation that would limit the “orphan drug” exclusion for 340B Drug Pricing Program rural and cancer hospitals. Specifically, the legislation would allow 340B critical access hospitals, sole community providers, rural referral centers and free-standing cancer hospitals to purchase orphan drugs at discounted rates through the 340B program as long as the orphan drug is used to treat illnesses or conditions other than the rare illnesses or conditions for which the orphan drug designation was originally given. “In an era of ever increasing prescription drug costs, this bill is an important step to ensure 340B hospitals subject to the orphan drug exclusion can obtain lifesaving drugs at a much needed discount so they can stretch limited resources to better serve their communities,” AHA wrote in a letter of support to Reps. Peter Welch, D-V.T., and David McKinley, R-W.Va., the bill’s sponsors.

Related News Articles

Headline
The Medicare for America Act could force one-third of American workers off employer-sponsored health insurance, according to a study by KNG Health Consulting…
Headline
A federal judge today reaffirmed her previous order to the Centers for Medicare…
Headline
AmerisourceBergen, Cardinal Health and McKesson today announced a $215 million settlement with two Ohio counties that claimed their practices contributed to…
Headline
The Centers for Disease Control and Prevention Friday released an update to its 1998 guidelines to prevent and control infection in the health care workplace,…
Chairperson's File
As we seek innovative ways to improve the health of our communities, it is more important than ever for hospitals and health systems to partner with others.
Headline
The House Energy and Commerce Committee last night approved a revised version of the Lower Prescription Drug Costs Now Act.